On September 28, 2012, Astex Pharmaceuticals, Inc. issued a press release announcing that the European Commission has approved the marketing authorization for DacogenŽ (decitabine) for Injection for the treatment of adult patients (age 65 and above) with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organization classification, who are not candidates for standard induction chemotherapy. Dacogen has also been granted Orphan Drug designation for the treatment of AML.

A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d)                 Exhibits



Exhibit
Number                                    Description

99.1 Press release issued by Astex Pharmaceuticals, Inc. on September 28, 2012